See more : Wafrah for Industry and Development Company (2100.SR) Income Statement Analysis – Financial Results
Complete financial analysis of Vascular Biogenics Ltd. (VBLT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vascular Biogenics Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Invesque Inc. (MHIVF) Income Statement Analysis – Financial Results
- Nareru Group Inc. (9163.T) Income Statement Analysis – Financial Results
- GasLog Partners LP (GLOP-PA) Income Statement Analysis – Financial Results
- Oracle Financial Services Software Limited (OFSS.BO) Income Statement Analysis – Financial Results
- Tacheng Real Estate Co.,Ltd. (6171.TWO) Income Statement Analysis – Financial Results
Vascular Biogenics Ltd. (VBLT)
About Vascular Biogenics Ltd.
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 658.00K | 768.00K | 922.00K | 562.00K | 585.00K | 13.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 104.00K | 365.00K | 394.00K | 163.00K | 235.00K | 340.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 554.00K | 403.00K | 528.00K | 399.00K | 350.00K | 13.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 84.19% | 52.47% | 57.27% | 71.00% | 59.83% | 97.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 21.65M | 22.70M | 19.66M | 15.47M | 15.94M | 17.77M | 12.45M | 11.20M | 10.97M | 13.51M | 10.57M |
| General & Administrative | 11.75M | 7.70M | 5.36M | 4.83M | 5.15M | 5.80M | 3.79M | 3.64M | 3.77M | 2.41M | 1.89M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 397.00K | 562.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.75M | 7.70M | 5.36M | 4.83M | 5.55M | 6.36M | 3.79M | 3.64M | 3.77M | 2.41M | 1.89M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 115.00K | 70.00K | 0.00 | 42.00K | 34.00K | 33.00K | 43.00K | 12.00K |
| Operating Expenses | 33.41M | 30.40M | 25.01M | 20.41M | 21.56M | 24.18M | 16.28M | 14.87M | 14.78M | 15.96M | 12.47M |
| Cost & Expenses | 33.51M | 30.76M | 25.41M | 20.58M | 21.79M | 24.52M | 16.28M | 14.87M | 14.78M | 15.96M | 12.47M |
| Interest Income | 634.00K | 120.00K | 363.00K | 870.00K | 908.00K | 335.00K | 263.00K | 100.00K | 15.00K | 27.00K | 236.00K |
| Interest Expense | 85.00K | 44.00K | 105.00K | 313.00K | 0.00 | 0.00 | 0.00 | 117.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.69M | 120.00K | 1.56M | 2.58M | 1.16M | 156.00K | 130.00K | 122.00K | 135.00K | 169.00K | 197.00K |
| EBITDA | -31.16M | -29.88M | -22.93M | -17.43M | -19.93M | -10.71M | -16.17M | -14.65M | -14.35M | -16.00M | -12.29M |
| EBITDA Ratio | -4,735.71% | -3,890.10% | -2,486.55% | -3,101.42% | -3,406.67% | -77.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -32.85M | -30.00M | -24.48M | -20.01M | -21.21M | -10.66M | -16.28M | -14.87M | -14.78M | -15.96M | -12.47M |
| Operating Income Ratio | -4,992.86% | -3,905.73% | -2,655.42% | -3,561.21% | -3,625.13% | -76.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 549.00K | 76.00K | 258.00K | 557.00K | 749.00K | 517.00K | 273.00K | -17.00K | -2.63M | -1.41M | 244.00K |
| Income Before Tax | -32.30M | -29.92M | -24.23M | -19.46M | -20.46M | -10.14M | -16.00M | -14.89M | -17.41M | -17.37M | -12.23M |
| Income Before Tax Ratio | -4,909.42% | -3,895.83% | -2,627.44% | -3,462.10% | -3,497.09% | -73.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -85.00K | -1.21M | 105.00K | 313.00K | -749.00K | -517.00K | -273.00K | 17.00K | 2.63M | 1.41M | -244.00K |
| Net Income | -32.22M | -28.71M | -24.33M | -19.77M | -20.46M | -10.14M | -16.00M | -14.89M | -17.41M | -17.37M | -12.23M |
| Net Income Ratio | -4,896.50% | -3,738.02% | -2,638.83% | -3,517.79% | -3,497.09% | -73.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.42 | -0.41 | -0.56 | -0.55 | -0.62 | -0.37 | -0.64 | -0.73 | -3.09 | -1.44 | -1.01 |
| EPS Diluted | -0.42 | -0.41 | -0.56 | -0.55 | -0.62 | -0.37 | -0.64 | -0.73 | -3.09 | -1.44 | -1.01 |
| Weighted Avg Shares Out | 77.55M | 69.33M | 43.67M | 35.88M | 32.97M | 27.40M | 24.97M | 20.31M | 5.63M | 12.05M | 12.05M |
| Weighted Avg Shares Out (Dil) | 77.55M | 69.33M | 43.67M | 35.88M | 32.97M | 27.40M | 24.97M | 20.31M | 5.63M | 12.05M | 12.05M |
Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q3 2020 Results - Earnings Call Transcript
Vascular Biogenics: Q3 Earnings Insights
VBL Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
VBL Therapeutics to Present at the H.C. Wainwright 6th Annual Israel Conference
VBL Therapeutics to Report Third Quarter 2020 Financial Results on November 16
Analysts Are Bullish on Top Healthcare Stocks: Vascular Biogenics (VBLT), Marinus (MRNS)
Source: https://incomestatements.info
Category: Stock Reports